A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon(R) in the Treatment of Subjects With a Diabetic Foot Ulcer

Trial Profile

A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon(R) in the Treatment of Subjects With a Diabetic Foot Ulcer

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2014

At a glance

  • Drugs CODA 001 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Therapeutic Use
  • Acronyms DUNE
  • Sponsors CoDa Therapeutics Inc
  • Most Recent Events

    • 30 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jul 2012 Status changed from not yet recruiting to recruiting, according to a CoDa Therapeutics media release.
    • 19 Jul 2012 Additional lead investigator (Mukker J) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top